Functional studies in vitro and in vivo identify a specific subset of CAFs termed glycolytic cancer-associated fibroblasts (glyCAF), which rely on glycolysis to impede cytotoxic T-cell entry into the tumor mass via the Cxcl16/Cxcr6 axis. The gene discussed is CXCR6; the disease is neoplasm.